Skip Navigation



Carcinogenesis Advance Access published online on July 4, 2003
Carcinogenesis, doi:10.1093/carcin/bgg109
© 2003 by Oxford University Press
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
24/9/1461    most recent
bgg109v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Simonnet, H.
Right arrow Articles by Godinot, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Simonnet, H.
Right arrow Articles by Godinot, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

CANCER BIOLOGY

Mitochondrial complex I is deficient in renal oncocytomas

Hélène Simonnet 1*, Jocelyne Demont 1, Kathy Pfeiffer 2, Leïla Guenaneche 1, Raymonde Bouvier 3, Ulrich Brandt 2, Hermann Schägger 2, and Catherine Godinot 1

1 CGMC (Center of Molecular and Cell Genetics), Unit 5534 of the CNRS and the University Lyon 1 Claude Bernard, Villeurbanne, France
2 Biochemie I, ZBC, Universitätsklinikum, Frankfurt am Main, Germany
3 Service of Anatomy and of Cytopathology, Hôpital Edouard Herriot, Lyon, France

* Corresponding author. E-mail: simonnet{at}univ-lyon1.fr.

Received 28 March 2003 ; revised 17 June 2003 ; accepted 18 June 2003

Abstract

Renal oncocytomas are benign tumors characterized by dense accumulation of mitochondria the cause of which remained unknown so far. Consistently, mitochondrial DNA content and the amounts and catalytic activities of several oxidative phosphorylation (OXPHOS) complexes were known to be increased in these tumors, but it was not ascertained that the OXPHOS system was functional. Here we investigated mitochondrial complex I and found that its NADH dehydrogenase activity and protein content were specifically decreased in oncocytomas, in stark contrast with the parallel decrease of all respiratory chain complexes in other, malignant, renal tumors. We conclude that deficiency of complex I in oncocytomas might be the early event causing the increased mitochondrial biogenesis, attempting to compensate for the loss of OXPHOS function. Since other tumors were found to be linked to mitochondrial deficiencies like genetic alterations of fumarate hydratase or succinate dehydrogenase, oncocytoma could be the third type of benign tumor associated with impairment of mitochondrial ATP production in an oxidative, quiescent tissue.

Besides, complex I enzyme activity was moderately decreased in the vicinity of oncocytomas, when compared to normal tissue adjacent to other renal tumors. This suggested that oncocytomas are the result of at least two serial modifications altering the mitochondrial respiratory chain.

oncocytoma, tumor, kidney, NADH dehydrogenase, mitochondria
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. A. Mayr, D. Meierhofer, F. Zimmermann, R. Feichtinger, C. Kogler, M. Ratschek, N. Schmeller, W. Sperl, and B. Kofler
Loss of Complex I due to Mitochondrial DNA Mutations in Renal Oncocytoma
Clin. Cancer Res., April 15, 2008; 14(8): 2270 - 2275.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
G. Gasparre, E. Hervouet, E. de Laplanche, J. Demont, L. F. Pennisi, M. Colombel, F. Mege-Lechevallier, J.-Y. Scoazec, E. Bonora, R. Smeets, et al.
Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma
Hum. Mol. Genet., April 1, 2008; 17(7): 986 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Gasparre, A. M. Porcelli, E. Bonora, L. F. Pennisi, M. Toller, L. Iommarini, A. Ghelli, M. Moretti, C. M. Betts, G. N. Martinelli, et al.
Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors
PNAS, May 22, 2007; 104(21): 9001 - 9006.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
M. Wu, A. Neilson, A. L. Swift, R. Moran, J. Tamagnine, D. Parslow, S. Armistead, K. Lemire, J. Orrell, J. Teich, et al.
Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells
Am J Physiol Cell Physiol, January 1, 2007; 292(1): C125 - C136.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
C. van Waveren, Y. Sun, H. S. Cheung, and C. T. Moraes
Oxidative phosphorylation dysfunction modulates expression of extracellular matrix--remodeling genes and invasion
Carcinogenesis, March 1, 2006; 27(3): 409 - 418.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. Jacques, O. Baris, D. Prunier-Mirebeau, F. Savagner, P. Rodien, V. Rohmer, B. Franc, S. Guyetant, Y. Malthiery, and P. Reynier
Two-Step Differential Expression Analysis Reveals a New Set of Genes Involved in Thyroid Oncocytic Tumors
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2314 - 2320.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
E. Hervouet, J. Demont, P. Pecina, A. Vojtiskova, J. Houstek, H. Simonnet, and C. Godinot
A new role for the von Hippel-Lindau tumor suppressor protein: stimulation of mitochondrial oxidative phosphorylation complex biogenesis
Carcinogenesis, March 1, 2005; 26(3): 531 - 539.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.